{"schema_version":"1","generated_at":"2026-10-30T17:42:52.672Z","data_as_of":null,"url":"https://www.findmykol.com/kol/carrie-ho","json_url":"https://www.findmykol.com/kol/carrie-ho/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"carrie-ho","name":"Carrie Ho","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of California, San Francisco","institution_url":"https://www.findmykol.com/institution/university-of-california-san-francisco","city":"San Francisco","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1720514821","orcid":"0000-0003-4437-9377","openalex":"A5088009215"},"summary":"Carrie Ho is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 39 publications with 329 citations (h-index 10); ClinicalTrials.gov lists 2 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":39,"cited_by_count":329,"h_index":10,"latest_activity_year":2026,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT07588698","title":"Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma","phase":"PHASE2","status":"NOT_YET_RECRUITING","role":"Overall official","sponsor":"Carrie Ho, MD","source_url":"https://clinicaltrials.gov/study/NCT07588698","trial_url":"https://www.findmykol.com/trial/NCT07588698"},{"nct":"NCT04545762","title":"Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma","phase":"PHASE1","status":"RECRUITING","role":"Overall official","sponsor":"C. Babis Andreadis","source_url":"https://clinicaltrials.gov/study/NCT04545762","trial_url":"https://www.findmykol.com/trial/NCT04545762"}],"source":"trials"},"payments":{"company_count":3,"program_years":{"first":2021,"last":null},"rows_total":3,"shown":3,"withheld":0,"rows":[{"payer":"ABBVIE INC.","program_year":2025,"amount_usd":107.61,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1720514821"},{"payer":"Genentech, Inc.","program_year":2025,"amount_usd":101.51,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1720514821"},{"payer":"Jazz Pharmaceuticals Inc.","program_year":2023,"amount_usd":99.55,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1720514821"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1720514821","source":"payments"},"prescribing":{"data_year":2020,"areas_total":3,"areas_shown":3,"areas":[{"area":"Cardiovascular","share_pct":70.2,"classes_total":4,"classes":[{"class":"Statin","setting":"prescribed","share_pct":21.4,"drugs":[{"name":"Atorvastatin Calcium","share_pct":100}],"max_beneficiaries":null},{"class":"Beta blocker","setting":"prescribed","share_pct":19,"drugs":[{"name":"Carvedilol","share_pct":100}],"max_beneficiaries":null}]},{"area":"Respiratory","share_pct":15.5,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":15.5,"drugs":[{"name":"Flovent Hfa","share_pct":100}],"max_beneficiaries":null}]},{"area":"Genitourinary & hormones","share_pct":14.3,"classes_total":1,"classes":[{"class":"5-alpha Reductase Inhibitor","setting":"prescribed","share_pct":14.3,"drugs":[{"name":"Dutasteride","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2020,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":38,"shown":5,"withheld":33,"matched_by":"OpenAlex author record","recent":[{"title":"CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS)","year":2026,"journal":"Journal of the National Comprehensive Cancer Network","source_url":"https://doi.org/10.6004/jnccn.2025.7411","status":"verified"},{"title":"Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2025029117","status":"verified"},{"title":"Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL","year":2025,"journal":"Blood Cancer Journal","source_url":"https://doi.org/10.1038/s41408-025-01236-6","status":"verified"},{"title":"Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era","year":2025,"journal":"American Journal of Hematology","source_url":"https://doi.org/10.1002/ajh.27760","status":"verified"},{"title":"Pembrolizumab + GVD with ctdna-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: A multicenter phase 2 Study of the University of California hematologic malignancies consortium","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-3630","status":"verified"}],"source":"works"},"contact":{"address_1":"400 PARNASSUS AVE FL 3","city":"San Francisco","state":"CA","zip":"941432202","phone":"415-353-9327","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1720514821","source":"identity"},"similar":[{"name":"Adil Daud","slug":"adil-daud","institution":"University of California, San Francisco","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/adil-daud","json_url":"https://www.findmykol.com/kol/adil-daud/profile.json"},{"name":"Emmanuelle Waubant","slug":"emmanuelle-waubant","institution":"University of California, San Francisco","specialty":"Neurology","url":"https://www.findmykol.com/kol/emmanuelle-waubant","json_url":"https://www.findmykol.com/kol/emmanuelle-waubant/profile.json"},{"name":"Peter Ganz","slug":"peter-ganz","institution":"University of California, San Francisco","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/peter-ganz","json_url":"https://www.findmykol.com/kol/peter-ganz/profile.json"},{"name":"Joel Palefsky","slug":"joel-palefsky","institution":"University of California, San Francisco","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/joel-palefsky","json_url":"https://www.findmykol.com/kol/joel-palefsky/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":33}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2024-11-09","provider_certified":"2024-11-09","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2020}},"methodology_url":"https://www.findmykol.com/about#methodology"}